Delcath Systems Inc. (DCTH) has delivered a strong performance in the first quarter of 2025, marked by significant revenue growth, its first-ever quarterly net income, and positive cash flow.
The company develops and commercializes interventional oncology treatments for liver cancers. Its flagship product is HEPZATO KIT, which is comprised of the chemotherapeutic drug Melphalan and Delcath's proprietary Hepatic Delivery System (HDS).
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com